0001104659-23-074985.txt : 20230627 0001104659-23-074985.hdr.sgml : 20230627 20230627070125 ACCESSION NUMBER: 0001104659-23-074985 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230627 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230627 DATE AS OF CHANGE: 20230627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 231043964 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 8-K 1 tm2319722d1_8k.htm FORM 8-K
0001178879 false 0001178879 2023-06-27 2023-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 27, 2023

 

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

  

001-33497

 

  

71-0869350

 

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

3675 Market Street, Philadelphia, PA 19104

(Address of Principal Executive Offices, and Zip Code)

 

215-921-7600

Registrant’s Telephone Number, Including Area Code

 

(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock Par Value $0.01   FOLD   NASDAQ

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 – Regulation FD Disclosure.

 

On June 27, 2023, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing European Commission approval of Opfolda® (miglustat) for late-onset Pompe disease. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Act, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Act.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits:

 

Exhibit No. Description
99.1 June 27, 2023 Press Release
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Signature Page

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMICUS THERAPEUTICS, INC.
Date: June 27, 2023 By: /s/ Ellen S. Rosenberg
  Name: Ellen S. Rosenberg
  Title: Chief Legal Officer and Corporate Secretary

 

 

 

 EX-99.1 2 tm2319722d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

 

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)

 

PHILADELPHIA, PA, June 27, 2023 – Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda® (miglustat) 65mg capsules, an enzyme stabilizer of cipaglucosidase alfa, a long-term enzyme replacement therapy for adults with late-onset Pompe disease. Pombiliti® (cipaglucosidase alfa) was previously approved by the EC in March 2023. Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid α-glucosidase (GAA). Amicus plans to immediately launch Pombiliti + Opfolda in Germany and is commencing reimbursement processes with healthcare authorities in other European countries.

 

“Late-onset Pompe disease is a rare, neuromuscular disorder that can have devastating consequences for patients and their families. The European Commission approval for Pombiliti and Opfolda is the realization of the work of so many individuals and teams dedicated to the mission of improving the lives of people living with Pompe disease. We look forward to bringing this much needed, new treatment to all adults living in the EU with late-onset Pompe disease,” said John F. Crowley, Executive Chairman of Amicus Therapeutics, Inc.

 

"We are extremely pleased with the EC approval of Pombiliti and Opfolda, and are grateful to the Pompe community around the world who have helped advance this therapy. Given the strength of the label and our launch readiness, we believe Pombiliti and Opfolda has the potential to become the next standard of care in for this devastating condition by showing that improvement is possible for people living with late-onset Pompe disease,” said Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc.

 

Pombiliti + Opfolda is a unique two-component therapy. Pombiliti (cipaglucosidase alfa), is a bis-M6P-enriched rhGAA enzyme, designed for increased uptake into muscle cells. Once in the cell, Pombiliti can be processed into its most active and mature form to break down glycogen. Opfolda (miglustat) is an enzyme stabilizer designed to stabilize the enzyme in the blood. The EC approval was based on clinical data from the Phase 3 pivotal study (PROPEL), the only trial in LOPD to study the real-world population of both ERT-naïve and ERT-experienced participants in a controlled setting.

 

“This significant milestone marks the beginning of broad access to Pombiliti and Opfolda for the LOPD community in Europe, where there is a high medical need for novel treatment options,” said Prof. Benedikt Schoser, Professor of Neurology at Ludwig-Maximilians-University of Munich LMU Department of Neurology. “In clinical studies, Pombiliti and Opfolda have exhibited clinically meaningful and positive changes in the key mobility and respiratory manifestations of this challenging disease. The EC approval and indication reflect the hope for the potential of this innovative therapy for people living with Pompe disease.”

 

“The Pompe community is greatly appreciative of Amicus’ long-standing commitment to develop a treatment option to address the continuing unmet needs of people living with late-onset disease. Each person deserves alternatives to help them best manage their condition,” said Tiffany House, President, International Pompe Association.

 

In the U.K., the Medicines and Healthcare products Regulatory Agency (MHRA) regulatory approval is expected in the third quarter of 2023. The U.S. Food & Drug Administration’s review is ongoing, and the Company expects approval in the third quarter of 2023. The FDA previously granted Breakthrough Therapy designation for Pombiliti + Opfolda.

 

About Pombiliti® + Opfolda®

 

Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that’s designed to reduce loss of enzyme activity in the blood. In clinical studies, Pombiliti + Opfolda was associated with demonstrated improvements in both musculoskeletal and respiratory measures.

 

 

 

 

About Pompe Disease

 

Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly deteriorating infantile form with significant impact to heart function, to a more slowly progressive, late-onset form primarily affecting skeletal muscle and progressive respiratory involvement. Late-onset Pompe disease can be severe and debilitating with progressive muscle weakness throughout the body that worsens over time, particularly skeletal muscles and muscles controlling breathing.

 

About Amicus Therapeutics

 

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

 

Important Safety Information

 

Pombiliti (cipaglucosidase alfa) Important Safety Information

 

Posology and Method of Administration: Pombiliti must be used in combination with miglustat 65 mg hard capsules. The recommended dose of Pombiliti is 20 mg/kg of body weight every other week. The Pombiliti infusion should start 1 hour after taking miglustat capsules. Paediatric population: The safety and efficacy of Pombiliti in combination with miglustat therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Life-threatening hypersensitivity to the active substance, or to any of the excipients. Contraindication to miglustat. Anaphylaxis and infusion-associated reactions (IARs): Serious anaphylaxis and IARs have occurred in some patients during infusion and following infusion with Pombiliti. Premedication with oral antihistamine, antipyretics, and/or corticosteroids may be administered to assist with signs and symptoms related to IARs experienced with prior enzyme replacement therapy (ERT) treatment. Reduction of the infusion rate, temporary interruption of the infusion, symptomatic treatment with oral antihistamine, or antipyretics, and appropriate resuscitation measures should be considered to manage serious IARs. If anaphylaxis or severe allergic reactions occur, infusion should be immediately paused, and appropriate medical treatment should be initiated. The current medical standards for emergency treatment of anaphylactic reactions are to be observed and cardiopulmonary resuscitation equipment should be readily available. The risks and benefits of re-administering Pombiliti following anaphylaxis or severe allergic reaction should be carefully considered, and appropriate resuscitation measures made available. Risk of acute cardiorespiratory failure in susceptible patients: Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions. Appropriate medical support and monitoring measures should be readily available during Pombiliti infusion. Immune complex-related reactions: Immune complex-related reactions have been reported with other ERTs in patients who had high IgG antibody titres, including severe cutaneous reactions and nephrotic syndrome. If immune complex-related reactions occur, discontinuation of the administration of Pombiliti should be considered and appropriate medical treatment should be initiated. The risks and benefits of re-administering Pombiliti following an immune complex-related reaction should be reconsidered for each individual patient. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Pombiliti in combination with miglustat, and for 4 weeks after discontinuing treatment. Pregnancy: Pombiliti in combination with miglustat therapy is not recommended during pregnancy. Breast feeding: It is not known if Pombiliti and miglustat are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Pombiliti in combination with miglustat therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reactions only attributable to Pombiliti were chills (4.0%), dizziness (2.6%), flushing (2.0%), somnolence (2.0%), chest discomfort (1.3%), cough, (1.3%), infusion site swelling (1.3%), and pain (1.3%). Reported serious adverse reactions only attributable to Pombiliti were urticaria (2.0%), anaphylaxis (1.3%), pyrexia (0.7%), presyncope (0.7%), dyspnoea (0.7%), pharyngeal oedema (0.7%), wheezing (0.7%), and hypotension (0.7%). Refer to SmPC for full list.

 

Opfolda (miglustat) 65 mg hard capsules Important Safety Information

 

Posology and Method of Administration: Opfolda must be used in combination with Pombiliti. The recommended dose is to be taken orally every other week and is based on body weight. Opfolda should be taken approximately 1 hour but no more than 3 hours before the start of the Pombiliti infusion. Paediatric population: The safety and efficacy of Opfolda in combination with Pombiliti therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Contraindication to cipaglucosidase alfa. Food Interaction: Patients should fast for 2 hours before and 2 hours after taking Opfolda. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Opfolda in combination with Pombiliti, and for 4 weeks after discontinuing treatment. Pregnancy: Opfolda crosses the placenta. Opfolda in combination with Pombiliti therapy is not recommended during pregnancy. Breast feeding: It is not known if Opfolda and Pombiliti are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Opfolda in combination with Pombiliti therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reaction only attributable to Opfolda 65 mg was constipation (1.3%). Refer to SmPC for full list.

 

 

 

 

Forward Looking Statement

 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data from a global Phase 3 study to investigate AT-GAA for the treatment of Pompe Disease, the potential implications on these data for the future advancement and development of AT-GAA and expectations regarding the regulatory process in the UK and US. There can be no assurance that the MHRA or FDA will grant full approval for both components of AT-GAA or when any such approvals may occur. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” "confidence," "encouraged," “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations and belief's which are subject to a number of risks, uncertainties and factors, including that the Company will not be able to successfully complete the development of, obtain full global regulatory approvals for, or successfully manufacture and commercialize AT-GAA once fully approved in each geography. In addition, all forward looking statements are subject to the other risks and uncertainties detailed in our Annual Report on Form 10-K for the year ended December 31, 2022. As a consequence, actual results may differ materially from those set forth in this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise this press release to reflect events or circumstances after the date hereof.

 

CONTACT:

 

Investors:

 

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations

afaughnan@amicusrx.com

+1 (609) 662-3809

 

Media:

 

Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications

dmoore@amicusrx.com

+1 (609) 662-5079

 

FOLD–G

 

 

 

 EX-101.SCH 3 fold-20230627.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fold-20230627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fold-20230627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2319722d1_ex99-1img01.jpg GRAPHIC begin 644 tm2319722d1_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 27, 2023
Entity File Number 001-33497
Entity Registrant Name AMICUS THERAPEUTICS, INC.
Entity Central Index Key 0001178879
Entity Tax Identification Number 71-0869350
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3675 Market Street
Entity Address, City or Town Philadelphia
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19104
City Area Code 215
Local Phone Number 921-7600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock Par Value $0.01
Trading Symbol FOLD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2319722d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001178879 2023-06-27 2023-06-27 iso4217:USD shares iso4217:USD shares 0001178879 false 8-K 2023-06-27 AMICUS THERAPEUTICS, INC. DE 001-33497 71-0869350 3675 Market Street Philadelphia PA 19104 215 921-7600 false false false false Common Stock Par Value $0.01 FOLD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "PXVU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " L.-M62I$[5NT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TEAA=#M1?&D(+B@> O)[&ZP24,RTN[;F];=+J(/X#$S?[[Y M!J8U49DAX7,:(B9RF&\FWX>L3-RR(U%4 -DM(VGSH M X+D? ,>25M-&F9@%5)KZ%JZ &4:8?/XNH%V)2_5/[-(!=DY.V:VI<1SKL5ER90&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M+#C;5F*IS%I/! ?! !@ !X;"]W;W)K=28)E_J? #"&D1R^7N('3_Q)-8;8T\T1H.$K?FV M6@X)LM2H^! ,!+&0^T^V.R3B**#9/!'@'0*\G'M_HYSREADV&FBU)=I>#6KV M('_4/!K@A+2S,C<:OA409T83]PFWV8=R+LCTQ>$:][03S7 M:_XWO $$!8978'BY7A/#('^/EZG1,%'_5!'M%5K5"K9ZK].$!7SH0'FF7+]R M9_3SC[3C_H;P-0N^)J8^NE5!!K5HR.(MX55P>'CO\B,"T2H@6JC*& C"G.(N M8NLJ"CQ^Q:*4(QSM@J-]7C)\KH4*R52&!(JO,B^X4E%&=774*= ZJ.!4&F'> MR)V(.'G(XF5U;>,:KDLOF\U6OXOP= N>[CD\3WPM;&5#SAY87)DH7&?\:39Y MGI/%A^G3V)\^+V:3^069/4RN$,9>P=@[AW$",ZI91&8RY#ORD;]54>)*+J2. M=GN];A_!ZA=8_7.P%FQ'9B&PB94(6.[DIR<65^S22[?7Z3?;+H)'W=(YW7, M9S)0.E$Z9[L@O!^0 M>[B./,IJ,ERRV>FVR2>F7V#- .>A\V"D90>@J(%_1SJQ(\CC0FUE)24NYV]$ MQ$(>)1O!,+ZR U#07&+SZ=Q# O&TRBX@$?;&$C9&2ANZ_ MWV(DI=%[N"F_9XI,=\&&R34_N6:K$7H8SV_'?V),I<-[9SG\-.9Z;;/T.RB8 MC76.A,GJ.?V?>X'&T5[2[LNAT<,=4Q+Q%0BY5UUP:[W?ZNX'1B7Y]G*I#&Q6 M\\,-A\ZK[07P_4HI\SZP.];B!X?1OU!+ P04 " L.-M6GZ ;\+$" #B M# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[ M=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2Q MQ'DJ?$,78&F? KP(&K X MU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_P MZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8Q MA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R M]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#. MRW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV0 M3NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_ MAOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#% MZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[ MC>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS M/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " L M.-M6EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0 M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L# M!!0 ( "PXVU:JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1 M;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IE ML]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1RE MW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B M]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@ M?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " L M.-M6)!Z;HJT #X 0 &@ 'AL+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):B MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% M @ +#C;5F60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9-- M3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/ MGI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3 M>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+ES MT&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JH MO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-( M9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX: M?^:+X3]>?P%02P$"% ,4 " L.-M6!T%-8H$ "Q $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( "PXVU9*D3M6 M[0 "L" 1 " :\ !D;V-0&UL4$L! A0#% @ +#C;5F*IS%I/! ?! M !@ ("!# @ 'AL+W=O7!E&UL4$L% 3!@ ) D /@( .43 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://amicustherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2319722d1_8k.htm fold-20230627.xsd fold-20230627_lab.xml fold-20230627_pre.xml tm2319722d1_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2319722d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2319722d1_8k.htm" ] }, "labelLink": { "local": [ "fold-20230627_lab.xml" ] }, "presentationLink": { "local": [ "fold-20230627_pre.xml" ] }, "schema": { "local": [ "fold-20230627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fold", "nsuri": "http://amicustherapeutics.com/20230627", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2319722d1_8k.htm", "contextRef": "From2023-06-27to2023-06-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://amicustherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2319722d1_8k.htm", "contextRef": "From2023-06-27to2023-06-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-074985-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-074985-xbrl.zip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